Abstract
The article discusses a court case AstraZeneca v European Commission regarding the antitrust scrutiny and the decision of the General Court of the European Union. The case was on the misuse of the procedural rules and antitrust with reference to the intellectual property rights of the pharmaceutical industry. Information on the abuse by the European Commission with reference to the US jurisprudence and the Walker Process Doctrine developed by the US Supreme Court is also presented.
| Original language | English |
|---|---|
| Pages (from-to) | 505-526 |
| Journal | European Competition Journal |
| Volume | 7 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 1 Dec 2011 |